What Is Point-of-Care Testing (POCT)?
Point-of-care testing (POCT) is diagnostic testing performed at or near the patient with results that support a clinical decision in the same encounter—lateral flow assays, benchtop analyzers, glucose meters, and molecular NAAT platforms. Evidence requirements match central-lab biomarkers: analytical validity, clinical validity, and fit-for-purpose context of use. Motif maps published POC biomarker evidence with PMIDs before assay or implementation studies.
TL;DR: Point-of-Care Diagnostics
- Point-of-care diagnostics (POCT) are tests performed at or near the patient, with results that support a management decision in the same clinical encounter (Engel et al., 2015)
- Common types include lateral flow assays, benchtop immunoassay analyzers, molecular NAAT platforms, and electrochemical devices such as glucose meters (Trifonova et al., 2020)
- Benefits include faster treatment decisions, reduced loss to follow-up, and broader access in decentralized settings; challenges include operator variability, quality assurance, and cost per test (Price, 2001; Pai et al., 2012)
- Biomarker POC programs need setting-specific analytical and clinical validity; central-lab cutoffs rarely transfer without revalidation (FDA-NIH, 2016; Thygesen et al., 2018)
- REASSURED criteria (Land et al., 2019) extend WHO ASSURED benchmarks with real-time connectivity and ease of specimen collection for modern POC devices
From the Motif team: Last reviewed June 2026. POC evidence is scattered across central-lab trials, analytical method papers, and deployment studies that rarely share the same specimen type or cutoff. Motif searches PubMed, PMC, and Europe PMC to extract biomarker–disease associations with PMIDs, tag study setting (bedside vs reference lab), and export cited summaries for design inputs or diligence, before assay teams copy the wrong literature into a cartridge program.
Point-of-care diagnostics, also called POCT, near-patient testing, or bedside testing, are medical tests run where care is delivered rather than in a distant central laboratory. Results typically return in minutes to a few hours, often while the patient is still present. That speed only matters when it changes what happens next: starting antibiotics, ruling out myocardial infarction, referring for confirmatory testing, or discharging with a clear plan (Engel et al., 2015).1
The concept is older than the acronym. Self-monitored blood glucose spread in the 1980s; pregnancy test strips and rapid strep assays followed. Today the menu spans infectious disease panels, cardiac biomarkers, coagulation monitoring, HbA1c, and molecular PCR cartridges in emergency departments and retail clinics alike (Trifonova et al., 2020).2 What unifies them is proximity to the patient and the expectation of an actionable readout, not merely a faster version of a send-out test.
What Are Point-of-Care Diagnostics?
StatPearls defines point-of-care testing as clinical laboratory testing performed at or near the site where patient care is delivered, with rapid turnaround that supports timely clinical decisions (Kost, 2023).3 ISO 22870 frames near-patient testing as testing performed near or at the site of a patient when the result may change care. Pai and colleagues emphasize a stricter operational definition: POC testing should yield a clear, actionable management decision within the same clinical encounter (treatment, referral, or confirmatory testing), not just a number on a printout (Pai et al., 2012).4
Price (2001) argued that decentralization shifts who performs testing and therefore which errors dominate: specimen collection, operator technique, storage conditions, and connectivity to the medical record matter as much as analytical sensitivity once the test leaves the reference laboratory. DOI: 10.1136/bmj.322.7297.1285. For biomarker programs, that shift is not a footnote. A troponin assay validated on venous plasma in a core lab and a fingerstick cartridge in an ambulance are different products under FDA-NIH BEST, even when they measure the same analyte (FDA-NIH, 2016).5
Core idea: Point-of-care diagnostics are defined by location, turnaround time, and clinical action, not by a specific technology platform.
How POC Testing Differs from Central Laboratory Testing
Traditional laboratory workflows batch specimens, run standardized quality systems under trained technologists, and return results hours or days later. Patients may leave before results arrive; follow-up rates drop. Pai et al. (2012) documented this loss-to-follow-up problem as a central rationale for infectious-disease POC in low- and middle-income settings, but the pattern appears in any setting where delayed results defer treatment.
POCT inverts parts of that model. Specimen transport disappears or shrinks. Turnaround compresses. Operators are often nurses, physicians, or patients themselves rather than laboratory scientists. Connectivity (getting results into the electronic health record in real time) becomes a bottleneck of its own when devices from multiple vendors lack interoperable interfaces (CLSI POCT1-A standards address this, but adoption remains uneven).
The trade-off is control. Central labs optimize precision across shifts; POC sites multiply variables. A 2020 review noted that POCT is only useful when pre-analytical steps, device maintenance, and interpretation algorithms are as disciplined as the assay brochure claims (Trifonova et al., 2020). Evidence supporting clinical benefit is still thinner for many analytes than marketing slides suggest.
Types of Point-of-Care Diagnostics
POC devices are often grouped by technology rather than disease. The boundaries blur: "Type 4" viscoelastic coagulation analyzers may sit beside the operating table but be operated by lab staff remotely, yet the categories below match how regulators, purchasers, and literature are organized.
Lateral Flow and Visual Read Rapid Tests
Lateral flow immunoassays (LFAs) use capillary action to move sample across a strip with capture antibodies and a visual or fluorescent read line. Pregnancy tests, many COVID-19 antigen assays, rapid strep screens, and fecal occult blood cards fall here. Turnaround is often under 20 minutes. Sensitivity and specificity vary widely by analyte; immunoassay POC for influenza and group A strep is standard in many clinics but may trail molecular methods for low-prevalence screening (Kost, 2023).
Benchtop Immunoassay and Clinical Chemistry Analyzers
Cartridge-based immunoassays and small chemistry analyzers deliver quantitative results for cardiac markers, BNP, CRP, drugs of abuse, electrolytes, and blood gases. Devices such as i-STAT-style platforms combine multiple analytes with hospital connectivity options. These systems approach laboratory precision when maintained, but require lot-to-lot verification, external quality assessment, and operator competency programs under ISO 22870.
Molecular Point-of-Care (NAAT) Platforms
Nucleic acid amplification at the bedside (PCR, isothermal amplification, or CRISPR-based detection) brought tuberculosis, respiratory virus, and sexually transmitted infection testing closer to the patient. Azar and Landry (2018) reviewed CLIA-waived molecular POC for influenza and RSV, noting the shift from culture-based reference methods to rapid nucleic acid detection in emergency and outpatient settings.6 Molecular POC generally offers higher sensitivity than antigen LFAs for respiratory pathogens, though detecting nucleic acid does not always imply active, treatable disease (Kost, 2023).
Electrochemical and Biosensor Devices
Glucose meters remain the most widely deployed POC category worldwide. Continuous and flash glucose monitoring extend the model into ambulatory diabetes care. Electrochemical sensors also support lactate, ketones, and some coagulation parameters. ISO 15197 and CLSI POCT12-A3 set performance expectations for glucose POC; real-world multi-site studies still find inconsistent compliance, which matters when insulin dosing depends on the readout.
Microfluidics and Emerging POC Formats
Microfluidic cartridges integrate sample preparation, reaction chambers, and detection on a chip, useful when only microliters of blood are available. Land et al. (2019) argued that future POC systems must meet REASSURED criteria (below), including ease of specimen collection and digital connectivity, not only analytical accuracy.7
Common Point-of-Care Diagnostic Examples
The table below is illustrative, not exhaustive. Intended use, regulatory class, and evidence base differ by jurisdiction and assay generation.
- Metabolic: blood glucose, HbA1c, ketones
- Cardiac: troponin I/T, BNP, NT-proBNP
- Infectious disease: influenza, SARS-CoV-2, strep A, HIV rapid antibody, molecular respiratory panels
- Inflammation / stewardship: CRP, procalcitonin
- Coagulation: INR, activated clotting time
- Pregnancy and urinalysis: hCG, urine dipsticks
- Drugs of abuse: multi-panel immunoassays
For protein biomarkers used in acute care, read our blog on protein biomarkers in disease diagnosis for troponin, procalcitonin, and natriuretic peptide evidence in depth. For how diagnostic biomarkers fit into the broader biomarker taxonomy, see our blog on what biomarkers are.
Related Articles in This Series
Go deeper on two high-intent topics that branch from this overview:
- Point-of-care vs laboratory testing: turnaround, accuracy, cost, and when each model fits clinically
- Molecular point-of-care diagnostics: RT-PCR cartridges, isothermal NAAT, GeneXpert, cobas Liat, and infectious-disease evidence
Where Point-of-Care Testing Is Used
POCT appears wherever delaying results would delay decisions:
- Hospitals: emergency departments, ICUs, operating rooms, stroke pathways
- Ambulatory care: primary care, urgent care, retail clinics, pharmacy-based testing
- Community and resource-limited settings: mobile clinics, rural health posts, home self-testing
- Non-traditional sites: workplaces, schools, disaster response; usage accelerated during the COVID-19 pandemic (Kost, 2023)
Engel et al. (2015) mapped diagnostic pathways across home, community, clinic, peripheral lab, and hospital tiers in India, showing that "point-of-care" is a continuum of actors and delays, not a single device category.1 Process innovation (how samples flow, who acts on results) often matters as much as product innovation (Schumacher et al., 2015).
Benefits of Point-of-Care Diagnostics
When implementation is disciplined, cited benefits include:
- Faster clinical decisions: antibiotic stewardship, chest pain rule-out, antiviral initiation
- Same-visit treatment: fewer patients lost between test order and result
- Workflow efficiency: reduced transport, phlebotomy bottlenecks, and bed days in selected pathways
- Access: testing where central laboratories are absent or overloaded
- Patient experience: immediate answers reduce anxiety and unnecessary return visits
Primary-care CRP point-of-care testing reduced antibiotic prescribing for respiratory infections by roughly 23–36% in randomized studies summarized by Cooke et al. (2015).8 Procalcitonin-guided algorithms reduced antibiotic exposure in acute respiratory infections without higher mortality in aggregate (Schuetz et al., 2017).9 Benefits depend on algorithms, not analytes alone.
Challenges, Quality Systems, and Regulation
POCT fails quietly when quality systems are treated as optional.
Operator Variability and Training
Decentralized testing spreads performance across hundreds of operators. ISO 22870 requires competence assessment, quality control, and documented comparability to reference methods. Kost (2023) lists six CLIA competency elements (direct observation, test monitoring, blinded proficiency, problem-solving review) that waived-test exemptions do not eliminate at accredited sites.
CLIA Complexity and FDA Oversight
In the United States, most waived POC tests are simple with low error risk; moderate-complexity POC requires stricter personnel and quality standards. FDA clearance or authorization defines intended use, specimen type, and performance claims. Sponsors moving biomarkers to POC must often repeat analytical validation with capillary blood, whole blood, or cartridge formats not identical to pivotal central-lab studies.
Cost, Connectivity, and Storage
Per-test cost often exceeds central-lab pricing; economic justification requires modeling avoided admissions, reduced imaging, or stewardship savings site by site. Cartridges and reagents are sensitive to heat, humidity, and light. Field conditions that reference labs rarely replicate. Results that never reach the chart do not improve care.
REASSURED: Modern POC Device Criteria
WHO's ASSURED criteria (Affordable, Sensitive, Specific, User-friendly, Rapid, Equipment-free, Deliverable) guided tropical-disease RDT development for years. Land et al. (2019) proposed REASSURED, adding Real-time connectivity and Ease of specimen collection to reflect digital health and patient-friendly sampling.7 The framework is widely used for global health POC and increasingly cited for device roadmaps in any market where decentralized testing must sync with surveillance, billing, and clinical decision support.
Biomarker Evidence at the Point of Care
Moving a validated central-lab biomarker to POC is a product development program, not a portability exercise. FDA-NIH BEST separates analytical validity (does the assay measure the analyte?), clinical validity (does the measurement associate with the state?), and clinical utility (does acting on it improve outcomes?) (FDA-NIH, 2016). A fast readout without utility is a throughput upgrade, not a clinical innovation.
Procalcitonin
Schuetz et al. (2017) meta-analyzed procalcitonin-guided antibiotic therapy in acute respiratory infections, finding reduced antibiotic exposure without higher mortality.9 POC procalcitonin devices now report concordance with central immunoassays: Trappel et al. (2015) validated B·R·A·H·M·S PCT direct on capillary and venous whole blood against reference methods, with median time to result 25 vs 147 minutes in European emergency departments.10 Yoo et al. (2019) found whole-blood POC procalcitonin correlated strongly with serum laboratory values in ED patients with suspected infection.11 Algorithm adherence remains the weak link: stewardship protocols, not the cartridge, drive utility.
Cardiac Troponin
Thygesen et al. (2018) define acute myocardial infarction around troponin dynamics with serial sampling above the 99th percentile URL plus ischemic context.12 High-sensitivity central-lab pathways enable 0/1-hour rule-out algorithms in many EDs. POC troponin must re-demonstrate limit of detection, delta criteria, and pre-analytical robustness on the matrix actually collected at bedside, often with lower analytical sensitivity than laboratory high-sensitivity assays. Claims extrapolated from hospital-lab PMIDs without cartridge-specific data are a common diligence failure.
Natriuretic Peptides (BNP / NT-proBNP)
Iwaz and Maisel (2016) reviewed POC natriuretic peptide testing for acute heart failure in emergency settings, where bedside turnaround can shorten time to diuretic therapy when operators follow validated algorithms.13 Site-specific comparability to central methods, age and renal-function-adjusted cutoffs, and operator training still require local verification before decentralized deployment.
Marshall et al. (2013) outline fit-for-purpose biomarker assay practices in drug development; the same staged validation applies when assays decentralize.14 Drucker and Krapfenbauer (2013) warn against skipping validation stages when moving from discovery to clinical use; miniaturization does not bypass them.15
Where POC Biomarker Programs Fail
- Extrapolating hospital-lab sensitivity and cutoffs to retail clinic or ambulance deployment without revalidation
- Ignoring cartridge lot variability, storage limits, and stability data absent from pivotal publications
- Mixing screening, monitoring, and companion-diagnostic intended uses in one evidence package
- Underbudgeting operator training, quality control staffing, and connectivity integration
- Pooling PMIDs that measured different specimen types, assay generations, or clinical algorithms
Diagnostic commercialization paths (regulatory, reimbursement, co-development) are covered in our blog on biomarker to diagnostic commercialization. POC adds decentralized validation on top of that stack.
How Researchers Use Motif for POC Evidence Review
Literature workflow is one piece; the harder problem is knowing which papers actually apply to your cartridge, indication, and care setting. Motif supports POC programs in several ways beyond a single search box:
- Setting-aware literature maps: query disease + biomarker + specimen type (fingerstick, capillary, whole blood) and extract performance metrics with PMIDs, then separate central-lab from bedside-sited studies before writing intended-use claims
- Competitive and precedent scanning: cross-reference analytes to UniProt, ClinVar, or PharmGKB and surface published comparator assays, cutoffs, and populations cited in registration-oriented papers
- Due diligence exports: structured, cited summaries for design inputs, IVDR/FDA briefing books, or investor memos without manually re-reading hundreds of abstracts
- Evidence grading: GRADE-adapted scoring helps teams prioritize PMIDs that match their context of use instead of treating all positive troponin or procalcitonin papers as interchangeable
- Gap detection: flag where analytical validation exists but clinical utility trials in the target setting do not, before manufacturing scale-up
Motif does not run clinical assays or replace regulatory consultants. It compresses the literature stage so analytical and clinical teams start from cited evidence rather than slide decks.
Frequently Asked Questions
What is the difference between point-of-care diagnostics and laboratory testing?
Point-of-care diagnostics are performed at or near the patient with rapid turnaround, often during the same visit. Central laboratory testing batches specimens off-site under trained technologists, with longer turnaround. POC shifts error risk toward collection, operator technique, and connectivity; central labs optimize analytical precision at scale (Price, 2001; Kost, 2023).
What are examples of point-of-care diagnostics?
Common examples include blood glucose meters, pregnancy tests, rapid strep and COVID-19 antigen tests, molecular respiratory PCR cartridges, ED troponin and BNP analyzers, INR monitors, CRP bedside tests, and HbA1c POC devices. The list grows as immunoassay and molecular platforms miniaturize (Trifonova et al., 2020).
Is point-of-care testing as accurate as laboratory testing?
It depends on the analyte, device, and site. Many quantitative POC immunoassays show strong correlation with reference methods when quality systems are followed, for example, procalcitonin POC vs central laboratory immunoassay in ED validation studies (Trappel et al., 2015; Yoo et al., 2019). Other analytes, especially high-sensitivity troponin, may not match central-lab detection limits without cartridge-specific studies. Accuracy claims require per-device, per-matrix evidence.
What is POCT vs POCD?
POCT (point-of-care testing) is the standard clinical and regulatory term. POCD sometimes appears informally for point-of-care diagnostics or devices, but literature, ISO standards, and CLIA guidance overwhelmingly use POCT or near-patient testing.
What standards govern point-of-care testing quality?
ISO 22870 defines quality and competence requirements for near-patient testing. CLSI publishes POCT-specific guidelines (including glucose and connectivity standards). In the U.S., CLIA categorizes test complexity; FDA regulates device intended use and performance claims. Operator training, quality control, and proficiency testing remain mandatory at accredited sites even for waived tests (Kost, 2023).
Why do point-of-care biomarker programs fail?
Common failures include copying central-lab cutoffs to capillary blood without revalidation, weak stewardship algorithms, poor EHR integration, inadequate operator training, and evidence packages that pool incompatible studies. Utility requires the right test, algorithm, and workflow, not speed alone (FDA-NIH, 2016; Drucker & Krapfenbauer, 2013).
How can researchers review POC biomarker literature efficiently?
Tag each source by study setting, specimen matrix, assay platform, and intended use before synthesis. Motif searches PubMed, PMC, and Europe PMC, extracts typed biomarker associations with PMIDs, and exports cited summaries so teams do not conflate central-lab pivotal trials with bedside analytical papers.
References
- Engel, N., et al. (2015). Point-of-care testing in India: missed opportunities. BMC Health Serv Res, 15, 550. PMID: 26652014
- Trifonova, D., et al. (2020). POCT: Current techniques and future perspectives. Clin Chim Acta, 501, 244-251. PMID: 31991154
- Kost, G.J. (2023). Point-of-Care Testing. In: StatPearls. PMID: 37276307
- Pai, N.P., et al. (2012). Point-of-care testing for infectious diseases in LMICs. PLoS Med, 9(4), e1001306. PMID: 23330251
- FDA-NIH Biomarker Working Group. (2016). BEST Resource. PMID: 27010052
- Azar, M.M., & Landry, M.L. (2018). Detection of influenza A and B viruses by CLIA-waived POC assays. J Clin Microbiol, 56(7). PMID: 29695519
- Land, K.J., et al. (2019). REASSURED diagnostics. Nat Microbiol, 4(1), 46-54. PMID: 30546093
- Cooke, J., et al. (2015). Narrative review of primary care POCT and antibacterial use in RTI. NPJ Prim Care Respir Med, 25, 15066. PMID: 25973210
- Schuetz, P., et al. (2017). Procalcitonin-guided antibiotics in respiratory infections. Cochrane Database Syst Rev, 10, CD007498. PMID: 29025194
- Trappel, E.S., et al. (2015). Validation of B·R·A·H·M·S PCT direct POC device in ED patients. Clin Chem Lab Med, 54(4), 577-584. PMID: 25884276
- Yoo, J.W., et al. (2019). Clinical value of whole blood procalcitonin POC in ED infection. Diagnostics, 9(2), 46. PMID: 31212806
- Thygesen, K., et al. (2018). Fourth universal definition of MI. Circulation, 138(20), e618-e651. PMID: 30571511
- Iwaz, J.A., & Maisel, A.S. (2016). Recent advances in POC testing for natriuretic peptides. Expert Rev Mol Diagn, 16(6), 641-650. PMID: 26919295
- Marshall, S., et al. (2013). Fit-for-purpose biomarker assays. Pharm Res, 31(6), 1313-1327. PMID: 24065593
- Drucker, E., & Krapfenbauer, K. (2013). Pitfalls in biomarker translation. EPMA J, 4(1), 7. PMID: 23442883
- Clinical and Laboratory Standards Institute. (2013). POCT12-A3 Point-of-Care Blood Glucose Testing.
- ISO. (2016). ISO 22870:2016 Point-of-care testing (POCT).
- Price, C.P. (2001). Point of care testing. BMJ, 322(7297), 1285-1288. DOI: 10.1136/bmj.322.7297.1285
- Schumacher, S.G., et al. (2015). Impact of POC implementation of Xpert MTB/RIF. Int J Tuberc Lung Dis, 19(6), 670-676. DOI: 10.5588/ijtld.14.0874
